Pfizer's Patent Cliff, Rising Debt, And The Fight To Stay A Buy

Pfizer is a Buy at low valuation but faces a 2030 patent cliff, COVID sales declines, and LOE risks. Click here to read an ...
Center on Budget and Policy PrioritiesOpinion

States Should Pursue New Revenue Options to Expand Access and Prevent Cuts to Affordable ...

States and localities have options to secure additional revenue for their efforts to address housing affordability.